Characteristics of Relapsed/refractory Diffuse Large B-cell Lymphoma Patients with Durable Responses to Maveropepimut-S, Pembrolizumab, and Cyclophosphamide: Long-term Follow-Up from the SPiReL Trial
EJHAEM(2025)
关键词
immunotherapy,large B-cell diffuse,lymphoma,therapeutics
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要